Our 7th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 9th - 10th March 2023, in London, would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.
This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.
With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy
Team Lead, Leucid Bio
Scientific Affairs Manager, Becton Dickinson
Chief Operating Officer, Cellecta
Senior Scientist, Malvern Panalytical
EU Business Head, Sanyou Bio
Technical Sales Specialist, Lunaphore
CEO, Precision ImmunoTherapeutics
Chief Scientific Officer, Proteome Sciences PLC
Associate Director, Business Development, Veracyte
Senior Scientist, Alligator Bioscience, Swed
Distinguished Research Professor and Wellcome Trust Senior Investigator,, Cardiff University
Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK
ILEC Conference Centre & Ibis London Earls Court, London